Cell permeable, potent and selective inhibitor of CDK1/cyclin B (IC50=25nM). Reported to affect the activities of other kinases only at much higher concentrations: PKCα (IC50=6.1µM), PKA (IC50=125µM) and EGFR (IC50>10µM). Induces mitochondrial damage and apoptosis in several human leukemia cell lines (>3µM).
Product Details
| Alternative Name: | N-(cis-2-Aminocyclohexyl)-N-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine |
| |
| Formula: | C19H24ClN7 |
| |
| MW: | 385.9 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Appearance: | White to yellow solid. |
| |
| Solubility: | Soluble in DMSO. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. Packaged under inert gas. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process: C. Yu, et al.; Cancer Res.
63, 1822 (2003),
Abstract;
2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors: P. Imbach, et al.; Bioorg. Med. Chem. Lett.
9, 91 (1999),
Abstract;
